pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Ozurdex
drug
save

dexamethasone LA

Marketedupdated 3mo ago
by $ABBV AbbVie Inc.
Approved
community read0 votes

🐶 often sniffed alongside

top 3
  • drugdexamethasone SR28 co-mentions · 14 sources
  • tagApproval28 co-mentions · 14 sources
  • drugOZURDEX14 co-mentions · 14 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 75 approved and 174 investigational indications.

indications

investigational
Diabetic Macular Edema

all catalysts(14)

approval · 14
Jun 17, 2009
approval
$ABBV249.46-0.54%
17y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Aug 31, 2010
approval
$ABBV249.46-0.54%
16y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 24, 2010
approval
$ABBV249.46-0.54%
16y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 24, 2012
approval
$ABBV249.46-0.54%
14y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 7, 2012
approval
$ABBV249.46-0.54%
14y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 7, 2014
approval
$ABBV249.46-0.54%
13y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Jun 28, 2014
approval
$ABBV249.46-0.54%
12y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Sep 26, 2014
approval
$ABBV249.46-0.54%
12y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Feb 5, 2016
approval
$ABBV249.46-0.54%
11y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
May 15, 2018
approval
$ABBV249.46-0.54%
8y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Oct 21, 2020
approval
$ABBV249.46-0.54%
6y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Dec 19, 2022
approval
$ABBV249.46-0.54%
4y ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
Mar 11, 2026
approval
$ABBV249.46-0.54%
5mo ago
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
TBD
approval
$ABBV249.46-0.54%
OZURDEX (DEXAMETHASONE) — FDA approval
dexamethasone LA
→
view all 14 catalysts →

Trials studying dexamethasone LA

  • phase3Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myelomarecruitingn=380
  • phase1A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myelomaactive not recruitingn=283
  • phase3A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)recruitingn=1,314
  • phase3Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patientsrecruitingn=824
  • phase2Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphomaactive not recruitingn=129
  • phase2Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.not yet recruitingn=228
  • phase4An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.recruitingn=100
  • phase2A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myelomarecruitingn=200
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Apr 7, 2028
~1.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

  • Apr 26, 2041method-of-use (U-1680)US 12144889
  • Jun 23, 2039formulationUS 11097061
  • Nov 16, 2037method-of-use (U-3455)US 11458041
  • Oct 7, 2036method-of-use (U-3455)US 12150896
  • Jun 22, 2034method-of-use (U-2340)US 10022502
  • May 23, 2034method-of-use (U-2340)US 10028965
  • May 23, 2034formulationUS 10159683
  • May 11, 2032formulationUS 10799642
  • May 14, 2030formulationUS 84096063.7y
  • Feb 12, 2030method-of-use (U-2487)US 85630273.5y

FDA exclusivities (1)

  • Apr 7, 2028NPPNew Product (3y)1.6y

News(0)

no news has mentioned this drug yet

brand
Ozurdex
generic
dexamethasone
MOA
12.1 Mechanism of Action Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.
indication
Branch Retinal Vein Occlusion
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?